The Food and Drug Administration (FDA) will reportedly weigh easing restrictions on peptides in anticipated talks.

The meeting, which is expected to be held in July, will discuss relaxing limits on more than a half dozen peptide injections.

Peptides are short chains of amino acids — the building blocks of proteins — that play key roles in biological functions, according to the National Institutes of Health. Peptide drugs are lab-made versions of natural molecules in the body that are designed to mimic or influence biological signals to treat disease, experts say.

PARALYZED MAN WALKS AGAIN AFTER EXPERIMENTAL DRUG TRIAL TRIGGERS REMARKABLE RECOVERY

In a federal notice released Wednesday, the FDA identified these drugs — used for conditions ranging from insomnia to obesity — for potential inclusion on a list of substances that can be safely compounded by pharmacies.

This follows Health and Human Services Secretary Robert F. Kennedy Jr.’s push to deregulate peptides, which he’s spoken about publicly, although most peptides have not been reviewed for safety by the FDA.

Kennedy has discussed using the substances for personal injuries. In a recent interview on “The Joe Rogan Experience” podcast, he stated that he’s a “big fan of peptides.”

ARE PEPTIDES THE FOUNTAIN OF YOUTH? DOCTORS WARN HYPE MAY OUTPACE SCIENCE

The HHS secretary mentioned that he’s “very anxious” to making some peptides “more accessible.”

“My hope is that they will get moved to a place where people have access from ethical suppliers,” Kennedy said, alluding to the FDA taking action.

What to know about peptides

Peptides have gained popularity among wellness influencers and fitness gurus as a means of building muscle, healing injuries or appearing younger, the AP reported.

CLICK HERE FOR MORE HEALTH STORIES

Peptides act like a signal to hormones and the human body. Similar to how GLP-1s (glucagon-like peptide-1 agonists), such as Ozempic, suppress appetite and trigger weight loss, peptides can signal other functions, like the release of growth hormones.

Certain peptides up for review by the FDA, like BPC-157, are marketed for tendon healing, gut healing (in cases like ulcerative colitis), injury recovery and inflammation reduction, although the FDA has warned about the risk of unapproved peptide treatments.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The FDA wrote in a February advisory that “compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”

“Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy,” the agency wrote.

The current peptide market has been referred to as the “Wild West” due to lack of regulation. In an interview with AP, Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest in Washington, D.C., commented that “the Wild West is about to become wilder.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“I don’t see why one would take the path of proper drug approval if there is now this less rigorous, alternative path to market,” he said.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Under the Biden administration, the FDA added nearly 20 peptides to a list of substances that should not be produced by compounding pharmacies, according to the AP.

The panel of pharmacy advisers at the time noted that the peptides did not meet criteria for safety.

The skyrocketing popularity of GLP-1 receptor agonists has transformed the weight-loss industry, but not all shots are created equal in terms of how they work.

A study published in Nature investigated how genes affect the success of modern weight-loss drugs — specifically, GLP-1s like semaglutide and tirzepatide.

In analyzing genetic data and self-reported weight loss from over 27,000 users, researchers pinpointed a specific variation in the GLP-1 receptor gene (GLP1R) that acts as a “booster” for the drug’s effectiveness.

POPULAR WEIGHT-LOSS MEDICATIONS LINKED TO HIDDEN SIDE EFFECTS, STUDY FINDS

Individuals carrying one copy of this variant lost an average of 1.6 pounds more than those without it, according to the findings.

This suggests that genetic testing could eventually help doctors steer sensitive patients toward medications they are more likely to tolerate.

“We believe these reports are a step forward in meeting an unmet need for a more informed and personalized approach to weight management,” said study co-author Noura Abul-Husn, chief medical officer at the 23andMe Research Institute in California, in a press release.

While this genetic “boost” is measurable, it remains relatively modest when compared to the total average weight loss of 24 pounds observed across the study population, the researchers noted.

SHOULD YOU MICRODOSE OZEMPIC? EXPERTS ARE SPLIT ON RISKS VS BENEFITS

Beyond genetics, other factors such as age, sex and specific medications remain much stronger predictors of success.

For instance, the study found that women generally saw a higher body mass index (BMI) reduction (12.2%) compared to men (10.0%).

The study may also reveal why certain patients experience stomach issues. Scientists identified a different genetic variant that was linked to increased reports of nausea and vomiting.

The presence of this side effect did not impact the drug’s effectiveness, however. Patients with variants in the GLP1R and GIPR genes lost just as much weight as those without it; they simply felt more sick during the process, the study found.

WEIGHT-LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS

“GLP-1 treatment decisions are complex, and having access to clinical expertise to help contextualize your genetic results alongside your full health picture is exactly the kind of guidance this report is designed to support,” said Abul-Husn.

Dr. Peter Balazs, MD, a hormone and weight-loss specialist serving the New York and New Jersey area, was not involved in the study but reiterated the role of the genetic variants in treatment response and side effects.

CLICK HERE FOR MORE HEALTH STORIES

“Notably, there appears to be a drug-specific effect: The GIPR variant associated with these side effects is observed with tirzepatide, but not with semaglutide,” he told Fox News Digital.

Balazs said he was surprised by the extremely wide nausea risk range (5%–78%). “Additionally, the drug-specific genetic dissociation was unexpected,” he added.

Study limitations

The data relied on participants reporting their own weight, which could be subject to bias.

“The data is self-reported and not medically verified, which may affect its reliability firstly,” Balazs told Fox News Digital. “It also does not account for key treatment variables, such as titration, discontinuation or dosing schedules.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The 23andMe participant pool may not reflect a diverse, real-world population, he added.

“The study also lacks data on important clinical endpoints, such as diabetes progression, and severe adverse effects, such as gastroparesis or pancreatitis,” Balazs pointed out. “Many of its findings also have not been supported by more clinically and statistically robust studies.”

For example, a sub-study comparing these reports to objective iPhone health data suggested that participants might over-report their progress. While users reported an 11.8% loss, electronic data in that subset showed a 5.8% loss.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

As an observational study rather than a controlled clinical trial, it could not definitively prove that the genetic variants caused the difference in weight loss, only that they are associated with it, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“I think this article is interesting, raising the possibility of genetic factors, and the use of genetic testing incorporated into further decision-making when picking weight-loss medications,” Balazs said. “However, I would be careful to draw conclusions solely based on this study.”

Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.